We have previously shown that the EphA2 receptor tyrosine kinase is overexpressed in glioblastoma multiforme (GBM) and represents a novel, attractive therapeutic target for the treatment of brain tumors. Here, we have developed an EphA2-targeted agent, ephrinA1-PE38QQR, a novel cytotoxin composed of ephrinA1, a ligand for EphA2, and PE38QQR, a mutated form of Pseudomonas aeruginosa exotoxin A. EphrinA1-PE38QQR showed potent and dose-dependent killing of GBM cells overexpressing the EphA2 receptor in cell viability and clonogenic survival assays, with an average IC 50 of f10 À11 mol/L. The conjugate was also highly effective in killing breast and prostate cancer cells overexpressing EphA2. The cytotoxic effect of ephrinA1-PE38QQR was specific, as it was neutralized by an excess of EphA2 ligands. Moreover, normal human endothelial cells and breast cancer cells that do not overexpress EphA2, as well as GBM cells that have down-regulated EphA2, were not susceptible to the cytotoxin. EphrinA1-PE38QQR
Introduction
Glioblastoma multiforme (GBM), a grade 4 astrocytoma, is the most common primary malignant brain tumor with dim prognosis. Despite the current standard treatment of surgery, radiation, and chemotherapy, the average survival of patients with GBM remains only 14 months (1). We have previously identified the EphA2 receptor tyrosine kinase as an attractive molecular target in GBM. EphA2, which is abundant in GBM cell lines and tissue specimens and absent in nonmalignant brain (2) , is a member of the largest family of tyrosine kinase receptors (3) . EphA2 is also overexpressed in a number of other solid tumors, including those of the breast (4), prostate (5), ovary (6) , and pancreas (7) . EphrinA1, a ligand for EphA2, is expressed at lower levels, differentially with respect to the receptor in GBM, leaving EphA2 predominately in an unactivated, nontyrosine-phosphorylated state despite being overexpressed (2), a pattern that has also been observed in breast cancer (8) . Importantly, this scenario results in abundant amounts of EphA2 that are available for binding by exogenous ephrinA1, potentially in the form of targeted therapies, such as cytotoxic proteins. The high-affinity Eph-ephrin complex has been shown to be internalized subsequent to ephrin-mediated activation of the cognate receptor (9, 10) . This crucial step would allow entry of ephrinA1-based therapeutics into the endosomal pathway, after which the delivery of other proteins, such as bacterial toxins, may take place.
Molecular-targeted therapies have emerged as a novel, specific approach to the treatment of malignancies. Bacterial toxins have been used in the construction of cytotoxic proteins designed to eliminate specific populations of malignant cells (11 -13) . Toxins such as Pseudomonas exotoxin A and diphtheria toxin are produced by highly pathogenic P. aeruginosa and Diphtheriae typhimurium, respectively, and are extremely potent and lethal to eukaryotic cells. Upon internalization of the bacterial toxin -containing agent into the endosomal pathway of the cell, the processing and translocation domain of the toxin facilitates its relocation to the cytosol, where the enzymatic domain ADP-ribosylates elongation factor-2, thereby halting protein synthesis and resulting in cell death (12, 14, 15) . For clinical/therapeutic application, the toxins are typically genetically modified to destroy their natural eukaryotic cell receptor -binding domain or are devoid of this domain. It is replaced by a moiety, such as a growth factor, monoclonal antibody, or soluble ligand that binds a tumor-specific molecule, such as a plasma membrane receptor, resulting in a molecularly targeted cytotoxin. Herein, we have used a truncated derivative of Pseudomonas exotoxin A, PE38QQR, which lacks the endogenous receptor -binding domain (domain I) of the toxin, has the three lysine residues in domain III substituted by two glutamines and an arginine, and has an added NH 2 terminal lysine that can be chemically modified to facilitate conjugation to another protein (16) . Some examples of clinically applied targeted cytotoxins are a transferrinbased diphtheria toxin -containing conjugate (17) , interleukin-2 (IL-2) -based diphtheria toxin -containing fusion proteins (e.g., DAB 389 IL-2; ref. 18) , and IL-13-based Pseudomonas exotoxin A -containing fusion proteins (e.g., hIL13PE38QQR; refs. 19, 20) . The former is Food and Drug Administration -approved for the treatment of hematologic malignancies based on phase I/II clinical trials and the latter is in phase III clinical trials for the treatment of recurrent GBM. Considering the resistance of GBM to current therapies and high rate of recurrence, molecularly targeted therapies using bacterial toxins represent an attractive option for the development of novel treatments that may improve the outcome of GBM patients.
Herein, we have used PE38QQR and a recombinant form of the ephrinA1 ligand fused to the Fc portion of IgG, ephrinA1-Fc, to create an ephrinA1-PE38QQR conjugate cytotoxin. This is the first attempt to create a cytotoxic therapy based on any of the ephrin proteins, of which there are two classes, A and B, and nine members that bind preferentially to the 16 A or B class Eph receptors, respectively (21) . We provide the first evidence that an ephrinA1-based targeted cytotoxin is effective in potently and specifically killing cancer cells overexpressing the EphA2 receptor.
Materials and Methods
Cell Lines,Tissues, and Reagents U-87 MG, U-251 MG, H4, SNB-19, U-373 MG, DBTRG-05, and human umbilical vascular endothelial cell (HUVEC) lines were obtained from American Type Culture Collection. MDA-MB-231 and PC-3 cells were obtained from the Cell and Virus Vector Core Facility at Wake Forest University School of Medicine. U-251[ephrinA1](+) cells were generated in our laboratory and are a stable cell line transfected with ephrinA1 as previously described (22) . G48a cells were primary high-grade astrocytoma human explant cell cultures isolated in our laboratory (23) . T47D cells were a generous gift from Dr. Darren Seals (Wake Forest University). Primary human dendritic cells were a generous gift from Dr. Martha Alexander-Miller (Wake Forest University) and were isolated and cultured as described previously (24) . All cells were grown in conditions as recommended by the manufacturer or, for G-48 cells, as described previously (23) . Staurosporine (Calbiochem) was used to treat cells at a concentration of 1 Amol/L for 4 h.
Chemical Conjugation of Proteins
Chemical conjugation is a well-established, effective method for the covalent cross-linking of proteins (25) .
Conjugation of ephrinA1 with PE38QQR was done using the Protein-Protein Cross-linking Kit (Molecular Probes) according to the manufacturer's instructions. Briefly, ephrinA1-Fc (R&D Systems) and PE38QQR (made inhouse; ref. 16) (1:3 molar ratio of ephrinA1-Fc to PE38QQR) were incubated with succinimidyl trans-4-(maleimidylmethyl)-cyclohexane-1-carboxylate or succinimydyl 3-(2-pyridyldithio)propionate, respectively, in a molar ratio of 10:1 succinimydyl 3-(2-pyridyldithio)propionate or succinimidyl trans-4-(maleimidylmethyl)-cyclohexane-1-carboxylate to protein in 0.1 mol/L sodium phosphate, 0.1 mol/L NaCl (pH 7.5) buffer for 1.5 h at room temperature with stirring. Derivatized proteins were purified away from the cross-linking reagents with spin-OUT 6000 micro columns (Chemicon). Thiolated PE38QQR was incubated in a 5:1 molar ratio [Tris (2-carboxy-ethyl)-phosphine-HCl to PE38QQR] of Tris (2-carboxy-ethyl)-phosphine-HCl for 15 min at room temperature to deprotect the protein and generate free thiols suitable for conjugation. The proteins were combined in a 1:3 molar ratio of ephrinA1-Fc to PE38QQR for 1 h at room temperature, then 4jC overnight. N-ethylmalemide was added at a concentration equal to that of the succinimydyl 3-(2-pyridyldithio)propionate and incubated for 30 min at room temperature, after which the conjugate was clarified for 5 min by high-speed centrifugation, subject to analysis by SDS-PAGE, and the supernatant stored at À80jC until further use.
Cell (26) . EphrinA1-Fc (R&D Systems) or ephrinA5-Fc (R&D Systems) at 1 Ag/mL was added 1 h before the cytotoxin, and cells treated with cycloheximide served as a positive control for cell death. Cells were incubated at 37jC for 48 h. Cell viability was determined using a colorimetric 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS)/phenazine methosulfate cell proliferation assay as recommended by the manufacturer (Promega). Cells were incubated with the MTS/phenazine methosulfate dye for 2 to 4 h, and absorbance was measured at 490 nm using a microplate reader. Each concentration of drug was tested in quadruplicate in each assay, and viability of cells treated with drug was calculated as percentage of untreated control cells.
Western Blotting
Western blotting was done as previously described (2). Cells were untreated or treated with ephrinA1-PE38QQR in serum-containing growth medium for the indicated times. Cell lysates were collected, separated by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and blocked with 5% milk in PBS + 0.05% Tween 20. Anti-EphA2 clone D7 (1:500) and anti -h-actin (1:50,000) were purchased Molecular Cancer Therapeutics 3209 from Sigma. Anti-EphA3 and anti-EphA4 (1 Ag/mL) were purchased from Zymed. Anti-EphA5 (1:200) was purchased from Santa Cruz Biotechnologies. Anti -P-AKT (1:1,000), anti-AKT (1:1,000), and anti-poly(ADP)ribose polymerase (PARP; 1:1,000) were purchased from Cell Signaling Technology, Inc. Membranes were incubated with secondary antibody conjugated with horseradish peroxidase (goat anti-mouse IgG or goat anti-rabbit IgG, Sigma), and detection was done using the enhanced chemiluminescence plus Western Blotting Detection System (GE Healthcare). Membranes were exposed to autoradiographic film X-OMAT AR for various times. Films were scanned at 600 dpi and images were compiled using Jasc Paint Shop Pro v 6.0.
Flow Cytometry
For flow cytometry analysis, 1 Â 10 6 cells were resuspended in 100 AL ice-cold PBS + 1% bovine serum albumin. Anti-EphA2 (10 Ag per reaction) was added for G48a, and U-373 MG GBM cells treated with various concentrations of ephrinA1-PE38QQR. In all cases, cells were also pretreated for 1 h with ephrinA1-Fc (ephrinA1-PE38QQR + ephrinA1 ), and in U-251 MG cells were treated with an unconjugated mixture of ephrinA1-Fc and PE38QQR proteins (ephrinA1-Fc + PE38QQR ). Points, mean; bars, SE. All assays were done in quadruplicate for each concentration of drug.
1 h. Cells were pelleted, rinsed twice with 1 mL PBS + 1% bovine serum albumin, and resuspended in 100 AL PBS + 1% bovine serum albumin. Anti-goat F(ab ¶)2 fragment antimouse IgG (H+L) -phycoerythrin (1:50; Beckman Coulter) was added to cells for 1 h. Cells receiving secondary antibody only or no antibodies served as negative controls. Cells were pelleted, rinsed with PBS + 1% bovine serum albumin, resuspended, and subjected to analysis of at least 10,000 events per sample by Becton Dickinson FACStarplus flow cytometer. For apoptosis studies, U-251 MG cells were treated with 6800 pmol/L of ephrinA1-PE38QQR in serum-containing growth medium for the indicated times, or were treated with 1 Amol/L staurosporine for 4 h. Cells were stained with propidium iodide and Annexin V using the Vybrant Apoptosis Assay Kit 3 (Molecular Probes) according to the manufacturer's instructions. Staurosporine-treated cells served as a positive control for Annexin V staining, whereas cells permeabilized with PBS + 0.1% Triton X-100 for 30 min at room temperature served as a positive control for propidium iodide staining. Cells were then subjected to analysis by flow cytometry as above, and at least 15,000 events were counted. Image analysis was done using FlowJo v7.2.2.
Clonogenic Cell Survival Assay U-251 MG or G-48a cells were seeded at 100, 300, 500, or 1,000 cells in 60-mm dishes and allowed to grow overnight. Growth medium was then replaced with medium containing various concentrations of ephrinA1-PE38QQR. After 48 h, medium containing the conjugate was removed and replaced with normal growth medium. Medium was changed every 2 to 3 days for 7 to 10 days. Cells were fixed in a solution of 10% methanol, 10% acetic acid, and stained with 0.4% crystal violet in 20% ethanol. Colonies with >50 cells were counted. Plating efficiency was calculated as (number of colonies formed on untreated plates / number of cells seeded) Â 100, and surviving fraction was calculated as number of colonies formed after treatment / (number of cells seeded Â plating efficiency). The data represent the mean F SD for each of three plates per concentration per cell number plated in each of two independent experiments for each cell line.
Caspase Inhibitor Studies U-251 MG cells were pretreated for 1 h with 50 Amol/L of the broad-spectrum caspase inhibitor zVAD-fmk (Calbiochem) or vehicle (DMSO) before addition of 6800 pmol/L ephrinA1-PE38QQR for 48 h. Cell lysates were then collected and subjected to Western blot analysis with an anti-PARP antibody; cell viability was determined by MTS assay; or cells were stained with Annexin V and propidium iodide and subjected to flow cytometry analysis.
Results

Production of the EphrinA1-PE38QQR Conjugate
To produce an ephrinA1-based cytotoxin, we did a chemical conjugation between ephrinA1-Fc, which is a disulfide-linked homodimer, and a truncated derivative of Pseudomonas exotoxin A, PE38QQR. Hetero-bifunctional cross-linking reagents were used to create a maleimide derivative of ephrinA1-Fc and a thiolate derivative of PE38QQR through its single, NH 2 -terminal lysine residue. SDS-PAGE analysis of the conjugate under nonreducing conditions revealed the presence of several higher molecular weight proteins corresponding to the predicted sizes of an ephrinA1-Fc homodimer conjugated to one, two, three, or four PE38QQR toxin moieties (Fig. 1A) . Although there is only one site on PE38QQR that is available for conjugation to ephrinA1-Fc, there are several sites within each ephrinA1-Fc that can potentially be chemically modified to take part in conjugation to PE38QQR. The two most abundant proteins migrated at f150 kDa, the expected size of a 1:1 conjugate of ephrinA1-Fc and PE38QQR, and f190 kDa, the expected size of a conjugate in which 2 PE38QQR toxins are covalently linked to one ephrinA1-Fc homodimer, representing together f75% of the conjugate (Fig. 1A) . There was no detectable ephrinA1-Fc (a protein migrating at 110 kDa) that was not conjugated to PE38QQR (Fig. 1A) . Importantly, the high molecular weight proteins corresponding to ephrinA1-PE38QQR conjugates were not observed in a mixture of the two proteins in the same molar ratio as the conjugation reaction but in the absence of cross-linking reagents (Fig. 1A) . Therefore, chemically derivatized ephrinA1-Fc and PE38QQR were efficiently linked together to form a novel ephrinA1-PE38QQR conjugate cytotoxin.
EphrinA1-PE38QQR Potently Kills GBM Cells Overexpressing the EphA2 Receptor
We tested the effect of the ephrinA1-PE38QQR conjugate on GBM cells that overexpress the EphA2 receptor. U-251 MG, SNB-19, DBTRG-05 MG, G48a, and U-373 MG are GBM cell lines that express abundant amounts of EphA2, detected by Western blotting as an immunoreactive band migrating at f130 kDa (Fig. 1B) . Furthermore, flow cytometry analysis on live, unfixed cells using a monoclonal anti-EphA2 antibody revealed the plasma membrane localization of the receptor in U-251 MG and G48a cells, but not U-87 MG cells (Fig. 1C) . EphrinA1-PE38QQR potently killed all the EphA2-overexpressing GBM cells after 48 h (Fig. 1D) . The IC 50 of the conjugate seemed to be in the range of 10 À11 mol/L, assuming a 1:1 stoichiometric linkage between ephrinA1-Fc and PE38QQR (Fig. 1A) . Notably, U-373 MG cells were less susceptible to killing by the conjugate than other GBM cell lines, as they least overexpress the EphA2 receptor (Fig. 1B and D) . To test the specificity of killing by the EphA2-targeted cytotoxin, we did experiments in the presence of unconjugated ephrinA1 ligand. Treatment with ephrinA1-Fc before addition of ephrinA1-PE38QQR completely neutralized the cytotoxic effect of the conjugate in all cells studied (Fig. 1D) . The specific and potent effect of the conjugate on U-251 MG cells was documented further by (a) treatment with a mixture of unconjugated ephrinA1-Fc and PE38QQR at EphA2 Receptor-Targeted Cytotoxin equimolar concentrations to the conjugate (Fig. 1D , U-251 MG cells and 2A) and (b) phase-contrast microscopy after treatment with 680 pmol/L of ephrinA1-PE38QQR ( Fig. 2A) . Treatment of U-251 MG cells with an unconjugated mixture of ephrinA1-Fc and PE38QQR did not affect GBM cells viability (Figs. 1D and 2A) . Furthermore, cells pretreated with the ephrinA1-Fc ligand before addition of ephrinA1-PE38QQR or those treated with unconjugated PE38QQR alone seemed morphologically normal (Fig. 2A) . In contrast, all of those cells treated with ephrinA1-PE38QQR were visually dead, which is in line with the results obtained using the cell viability assay (Figs. 1D and  2A) . Notably, the effect of ephrinA1-PE38QQR on U-251 MG cells was comparable with the effect of IL13.E13K-PE38QQR ( Fig. 2A) , a potent anti-GBM targeted cytotoxin that was previously developed by our laboratory (26) .
To further show the killing effect of ephrinA1-PE38QQR, the conjugate was also tested on G48a and U-251 MG cells using clonogenic cell survival assays. Consistent with our results from cell viability assays, treatment of these EphA2-overexpressing GBM cells for 48 h with ephrinA1-PE38QQR resulted in a potent, dose-dependent killing of cells (Fig. 2B) .
EphrinA1-PE38QQR Kills Breast and Prostate Cancer Cells that Overexpress EphA2
To determine the potential usefulness of ephrinA1-based cytotoxic therapies against solid tumors other than GBM, we tested the effect of ephrinA1-PE38QQR on breast and prostate cancer cells in which the EphA2 status had been documented previously (4, 5, 8) . First, we confirmed the reported overexpression of EphA2 in MDA-MB-231 breast carcinoma cells and in PC-3 prostate cancer cells by Western blotting (Fig. 2C) . Accordingly, we found that MDA-MB-231 and PC-3 cells were susceptible to the cytotoxic effect of ephrinA1-PE38QQR (Fig. 2D) . Moreover, the cytotoxicity was specific, as the effect was blocked by the presence of ephrinA1 ligand alone (Fig. 2D) .
EphrinA1-PE38QQR Acts Specifically through the EphA2 Receptor
To further test the specificity of ephrinA1-PE38QQR for EphA2 receptor -expressing cells, we used several cell lines that express low or undetectable levels of EphA2, either naturally or as a result of EphA2 down-regulation (Fig. 3A) . T47D breast cancer cells do not express any detectable EphA2, whereas HUVECs express EphA2, but at lower levels when compared with GBM cells (Fig. 3A) . Two other cell lines that we have shown previously to exhibit low EphA2 are a sub -cell line of U-87 MG GBM cells and H4 malignant glioma cells (Figs. 1C and 3A; ref. 2 ). In addition, U-251 MG cells that have been stably transfected with ephrinA1 (U-251 [ephrinA1](+)) exhibit down-regulated EphA2 compared with controls ( Fig. 3A; ref. 22 ). These cell lines responded only minimally, if at all, to the treatment with the highest concentrations of ephrinA1-PE38QQR, which is in support of the targeted specificity of the ephrinA1-cytotoxin for EphA2 receptor-overexpressing cells (Fig. 3B) . In an attempt to address a potential immunosuppressive effect of ephrinA1-PE38QQR, we have also tested normal dendritic cells and found that these cells are not responsive to the conjugate at all (Fig. 3B, DC) . In addition, pretreatment of U-251 MG cells with ephrinA1-Fc did not neutralize the effect of IL13.E13K-PE38QQR, a cytotoxin that is targeted to IL-13Ra2 (Fig. 3C) , clearly demonstrating the specific ability of ephrinA1-Fc to neutralize EphA2-targeted cytotoxins.
A functional interaction between ephrinA1 and EphA2, resulting in receptor activation, has been shown to be followed by EphA2 internalization and down-regulation (27) . To show that ephrinA1-PE38QQR is acting specifically through the EphA2 receptor, we did Western blotting for EphA2 on U-251 MG cells treated with the conjugate over time (Fig. 4A) . EphA2 was down-regulated within 4 h of treatment with ephrinA1-PE38QQR, was undetected by 8 h, and remained undetectable through 48 h in the presence of the conjugated ligand (Fig. 4A) . Ephrin ligands are divided into ''A'' and ''B'' classes based on the Eph receptors with which they interact. The ephrinA ligands exhibit promiscuous binding to members of the EphA receptor family, due in part to the high sequence homology between the A-class ephrins (28) . Hence, the possibility exists that other EphA receptors may interact with the ephrinA1 conjugate. Thus, we have analyzed the expression of EphA3, EphA4, and EphA5 by Western blotting in GBM and HUVEC cells (Fig. 4B) . EphA3, EphA4, and EphA5 were not nearly expressed compared with EphA2 GBM cells, which all are potently killed by the conjugate (Figs. 1B, D and 4B) . Interestingly, EphA3 was overexpressed in U-373 MG cells, and EphA4 was overexpressed in HUVEC, the two cell lines that do not overexpress EphA2 and were less or not at all susceptible to killing by the ephrinA1 conjugate, respectively (Figs. 1B,  D, 3A, B, and 4B) . Thus, the susceptibility to killing by ephrinA1-PE38QQR parallels the degree of EphA2 overexpression in cells and not the expression of other EphA receptors, which further supports the specificity of the ephrinA1-conjugate for EphA2-overexpressing cells.
Furthermore, other members of the ephrinA family may serve as ligands for EphA2. We thus tested the ability of ephrinA5, another ephrin ligand shown previously to bind to and activate EphA2 (28) , to neutralize the effect of ephrinA1-PE38QQR. Pretreatment of U-251 MG cells with ephrinA5-Fc rescued cells from killing by the conjugate in a similar manner to ephrinA1-Fc, further demonstrating the specific EphA2-mediated cytotoxicity of ephrinA1-PE38QQR, because this cell line does not overexpress EphA3, EphA4, or EphA5 (Fig. 4B and C) . We have also done a pilot dose-escalation toxicity study in nude mice harboring U-251 MG s.c. xenograft tumors, and have found no toxicity with a dose of up to 8 Ag/mouse injected intratumorally (five mice per group) that compares very favorably with cytotoxins against the target expressed in tissues of mice that cross-reacts with a human ligand. We also observed a 56% decrease in tumor burden in ephrinA1-PE38QQR -treated mice compared with vehicletreated animals.
EphrinA1-PE38QQR Induces Caspase-Dependent Apoptosis that Is Not Required for Cell Killing
Eukaryotic cell death in response to Pseudomonas exotoxin A has been shown previously to result from the arrest of protein synthesis after inactivation of elongation factor 2, as well as from apoptosis (29, 30) . To address the specific EphA2 Receptor-Targeted Cytotoxin question of whether ephrinA1-PE38QQR -mediated cytotoxicity toward EphA2-expressing GBM cells has an apoptotic component, we stained U-251 MG cells treated with the conjugate for 12, 24, or 48 h with Annexin V and propidium iodide, and analyzed by flow cytometry (Fig. 5A) . We detected a substantial increase in the proportion of cells staining positive for Annexin V (up to 30%), and thus undergoing apoptosis after 48 h (Fig. 5A) . We also observed a moderate increase in the proportion of cells positive for both Annexin V and propidium iodide and undergoing late apoptosis/necrosis at this 48 h time point (Fig. 5A) . To examine whether the apoptosis we observed is dependent on caspase activation, we examined the expression of PARP in U-251 MG cells treated with the conjugate (Fig. 5B) . Western blotting revealed the characteristic pattern of PARP cleavage from a 116 kDa protein to an 89 kDa fragment that occurs during caspase-dependent apoptosis (refs. 31, 32; Fig. 5B ). Cleaved PARP was first detected at 24 h of treatment with ephrinA1-PE38QQR, and also in cells treated with staurosporine as a positive control (Fig. 5B) . Treatment of cells with the broad-spectrum caspase inhibitor z-VAD-fmk abrogated the cleavage of PARP at 48 h in response to ephrinA1-PE38QQR (Fig. 5B) . Furthermore, z-VAD-fmk blocked the majority, but not all, of the apoptosis from occurring in response to the conjugate as shown by flow cytometry (Fig. 5C) . To address the question of whether this caspase-dependent apoptotic component is required for exerting a full cytotoxic effect of ephrinA1-PE38QQR, we did cell viability assays on cells treated with the conjugate for 48 h in the presence of z-VAD-fmk or vehicle alone (Fig. 5D) . Although z-VADfmk inhibited PARP cleavage and apoptosis in response to ephrinA1-PE38QQR (Fig. 5B and C) , this inhibition of caspase-dependent apoptosis did not affect the ability of ephrinA1-PE38QQR to kill U-251 MG cells (Fig. 5D) . Thus, caspase-dependent apoptosis is induced in response to ephrinA1-PE38QQR, but it is not required to achieve the killing of cells.
EphrinA1-PE38QQR Does Not Change the Activity of Phosphoinositide 3-Kinase Pathway
We investigated the possibility that ephrinA1-PE38QQR could elicit intracellular signaling through the EphA2 receptor or otherwise, potentially causing alterations in pathways such as phosphoinositide 3-kinase/AKT, the inhibition of which could lead to the mediation/potentiation of conjugate effect in GBM cells (33, 34) . U-251 MG cells treated with ephrinA1-PE38QQR over time exhibited no changes in phosphorylation of AKT, as detected by Western blotting (Fig. 6A) . Also, to determine the period of time of exposure to the conjugate required to evoke an irreversible path to cell death, U-251 MG cells were treated with ephrinA1-PE38QQR for various times; the drug was removed and replaced with drug-free medium; and cells were left in culture for a total of 48 h. Even a very short, 1-h exposure to the conjugate was capable of inducing cell killing (Fig. 6B) . Thus, a short exposure to the conjugate resulting in the delivery of the toxin inside cells overexpressing the EphA2 receptor is responsible for GBM cell death.
Discussion
In the present work, we have produced a novel antitumor cytotoxin, ephrinA1-PE38QQR, based on the ephrinA1 ligand and a truncated form of Pseudomonas exotoxin A, which is targeted to EphA2 receptor -expressing tumor cells. We have provided for the first time evidence for potent and specific cytotoxic activity of an ephrinA1-based conjugate. EphrinA1-PE38QQR is extremely potent and kills EphA2-expressing GBM, breast, and prostate cancer cells at an IC 50 of f10 À11 mol/L. EphrinA1-PE38QQR represents a novel agent potentially suitable for the specific delivery of a potent cytotoxic anticancer drug while sparing nonmalignant tissue, which is especially important with respect to the treatment of malignant brain tumors. For example, patients that do achieve prolonged survival often experience cognitive impairment due to the intense treatment regimen, particularly as a result of radiation-induced injury to normal brain tissue (35) . EphrinA1-PE38QQR takes advantage of the fact that the EphA2 receptor tyrosine kinase is abundantly overexpressed in the majority of GBM patient tumors and not in normal brain (2) . The overexpression of EphA2 in GBM is not surprising considering its functional role in contributing to malignancy. We have shown previously that the receptor is important in promoting GBM cell invasion and anchorage-independent growth in its unactivated, non -tyrosine-phosphorylated form, the state in which it is found in GBM tumors (2) . In fact, EphA2 has been identified as an oncoprotein capable of transforming mammary epithelial cells in its non -tyrosinephosphorylated state (4) and, importantly, has ligandindependent kinase activity (36) . Others have identified ephA2 as one of a small group of genes that are upregulated by EGFRvIII, a constitutively active form of epidermal growth factor receptor that is present in a subpopulation of patients with GBM (37) . Moreover, a recent study has shown a positive correlation between EphA2 expression and poor survival of GBM patients (38) . Thus, although the approach in this study was to target cytotoxic agents to destroy malignant cells via EphA2, there is also a possibility that the conjugate will suppress malignant properties of tumor cells by activating signaling through the receptor and/or by decreasing the presence of the EphA2 oncoprotein (39 -41) . In fact, we have shown herein that ephrinA1-PE38QQR causes down-regulation of EphA2 over time, which also serves as an indication that ephrinA1 in the conjugate makes a productive contact with EphA2 receptor (27) .
The specificity of ephrinA1-PE38QQR for EphA2 was shown through its inability to kill cells not overexpressing the receptor, even when these cells expressed other members of the EphA receptor family. Although other EphA receptors may be present in GBM, we have found that they are generally not overexpressed to the degree that we have observed for EphA2, which is supported by gene expression analysis of both GBM patient samples and cell lines (42) . Despite the overexpression of EphA3, U-373 MG cells were one of the least susceptible to the conjugate and, accordingly, expressed significantly less EphA2 than other cell lines that were potently killed. Furthermore, we observed no significant killing of HUVECs despite their overexpression of EphA4, in addition to the low levels of EphA2 found in these cells. These observations suggest that a cytotoxic response to the ephrinA1-PE38QQR conjugate is specifically mediated by EphA2 and potentially depends both on the level of expression of membrane-localized receptor as well as the affinity of ephrinA1 for this receptor.
The EphA2 receptor is overexpressed and functionally important in a number of peripheral solid tumors. This, in combination with our data presented here that ephrinA1-PE38QQR is effective in killing both breast and prostate cancer cells expressing high levels of EphA2, make targeting the EphA2 receptor with ephrinA1-based cytotoxins a potentially attractive therapeutic strategy for the treatment of other malignancies in addition to GBM. We envision the local administration of ephrinA1-based cytotoxins to the brain via convection-enhanced delivery, an effective method for the local delivery of recombinant cytotoxins based on positive pressure via catheters placed at the site of delivery (43, 44) . Moreover, the local delivery of targeted cytotoxins to the tissue surrounding the resection cavity after surgery may potentially destroy remaining, infiltrative GBM cells. These invasive tumor cells typically harbor increased activity of survival pathways such as phosphoinositide 3-kinase/AKT, are less susceptible to apoptosis-inducing therapeutic agents such as chemotherapy and radiation (33) , and are thought to be responsible for the recurrence of tumors that directly contribute to the poor outcome of GBM patients. In fact, we have observed EphA2 to be expressed at high levels in GBM cells invading into the normal brain tissue surrounding the tumor. 3 An additional, important benefit of ephrinA1-PE38QQR and other EphA2-targeted cytotoxins of this nature is the fact that EphA2 is highly overexpressed in some cases in the tumor-associated vasculature (45 -47) . Therefore, whereas many therapies are targeted specifically either to tumor cells or tumor-associated vasculature, ephrinA1-PE38QQR has the potential benefit of being effective in destroying both simultaneously, thus conferring a great advantage over other therapies.
In the process of ephrinA1-PE38QQR -induced cytotoxicity in EphA2-overexpressing cells, the signature of caspase-dependent apoptosis is present. However, we observed that inhibition of caspases had no effect on the ability of ephrinA1-PE38QQR to kill cells, indicating that this process is not required for conjugate-mediated cell death. Indeed, it has been shown previously that Pseudomonas exotoxin A induces caspase-dependent apoptosis (29, 48) , but this process only occurs after the arrest of protein synthesis due to ADP-ribosylation of elongation factor-2 and is not necessary for cell death (29, 49) . Based on our results, it is likely that ephrinA1-PE38QQR acts through a similar mechanism, with cell death having an apoptotic component that is a secondary effect of the arrest of protein synthesis. Considering that many cancer cells, and in particular GBM cells, harbor resistance to apoptosisinducing drugs, it is advantageous from a therapeutic standpoint that ephrinA1-PE38QQR is not dependent on this process to induce cell death.
The data that we have presented here with respect to ephrinA1-PE38QQR -induced cytotoxicity are significant, as we observed killing of GBM cells similar in effect to that seen with IL-13.E13K-PE38QQR, an IL-13 -based recombinant cytotoxin targeting IL-13Ra2, which is extremely potent in destroying GBM cells (26) . An attractive possibility arises of combining ephrinA1-based antitumor cytotoxins with others, such as those targeting IL-13Ra2, with the ultimate goal of a combinatorial therapy that will be effective in all patients despite the known heterogeneity of GBM tumors. In fact, we have analyzed the combined expression of IL-13Ra2 and EphA2 in malignant gliomas and have found that nearly 100% of GBM patient samples analyzed express at least one of these molecular targets (50) .
In summary, this work serves as a proof of principle that an ephrinA1-based cytotoxin is effective against malignancies expressing the EphA2 receptor. It is the first attempt at the development of a cytotoxic therapy based on any of the ephrin proteins of either class. Moreover, these data form the basis for the further preclinical development of ephrinA1-based cytotoxins that can be used alone or in combination with existing therapies to improve the outcome of patients with GBM and other EphA2-overexpressing malignancies.
